ClinicalTrials.gg
CompletedNCT04230070Updated Feb 10, 2021

Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product

A Phase 1 interventional study of Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug and Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product in Bioequivalence, sponsored by Laboratorios Andromaco S.A.. Completed at 1 site in Chile. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-10.

Sponsored by Laboratorios Andromaco S.A. (part of Grünenthal GmbH) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

This Pivotal study will investigate the bioavailability in women of 2 tablet formulations containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The Pivotal study will be performed at a single site with 30 subjects. Participants will take 2 tablets of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 14 days between each study period.

Read the detailed description

The primary objective of the study is to investigate the relative bioavailability of Levonorgestrel and Ethinyl estradiol of 2 tablet formulations with Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg and to demonstrate bioequivalence of both formulations in terms of rate and extent of absorption:

  • Test Product: Product manufactured by Laboratorios Andrómaco S.A.
  • Reference Product: Microgynon [Trademark], product of Bayer AG, Germany. The 90% confidence intervals for the intra-subject coefficient of variation (Test versus Reference Product) for the main pharmacokinetic parameters área under the plasma concentration-time curve from time zero to time t (AUC0-t) and from time zero to 72 hours (AUC0-72), and maximum plasma concentration (Cmax) for total Levonorgestrel and Ethinyl estradiol will be determined.

Participants will be confined in the study site for approximately 36 hours during each study period (for 12 hours pre-dosing and for 24 hours post dosing) during which pharmacokinetic (PK) blood samples will be obtained. 16 blood samples will be taken up to 24 hours after the administration in each period. Participants will return to the site to provide additional blood samples at 48 h, and 72 h postdose.

The washout period between the two study periods will be at least 14 days. The samples from each participant will be analyzed with 2 methods of highperformance liquid chromatography-tandem mass spectrometry bioanalytical assays to quantify total Levonorgestrel and Ethinyl estradiol in plasma.

The safety objective is to evaluate the tolerability of both formulations in women by collecting adverse events.

02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

Laboratorios Andromaco S.A. is the lead sponsor of 19 studies on the registry; none are open to participants now.

First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-pregnant and non-breastfeeding women
  • Women of childbearing age with an acceptable form of during the study
  • 18 to 55 years old inclusive; greater than or equal to 18.51 and less than or equal to 29.99
  • Non-smoking or smoke only 3 cigarettes every 7 days
  • With results of laboratory tests, and chest radiography in normal and / or negative or abnormal ranges but without clinical relevance and declared suitable for study by the doctor after the physical examination
  • Capable to understand the Form

Exclusion criteria

Exclusion Criteria:

  • Study site or sponsor staff or any of their family members
  • With history of drug and/or alcohol abuse
  • Smokers more tan 3 cigarettes every 7 days
  • Vitamin supplements intake 7 days prior to the administration of the medications under study
  • Any recent change in eating habits or physical exercise
  • Using of a pharmacological therapy (except over the counter medication use 7 days prior to the study)
  • to the study drug or to other chemically related compounds, history of serious adverse reactions or hypersensitivity to any medication
  • Use, during the 28 days prior to the start of the study, of medications known to alter liver enzyme activity
  • Consumption of beverages or food containing grapefruit or pink grapefruit, within 7 days prior to each administration of the study medication and consumption of alcohol, caffeine or beverages or foods containing xanthines 24 hours before each administration of the study medication until the last sample of each period
  • History of any significant cardiovascular disease
  • Acute disease that generates significant physiological changes from the time of selection until the end of the study
  • , and/or C positive
  • Presence or history of thrombophlebitis, thrombosis or thromboembolic disorders, deep vein thrombosis, pulmonary embolism or known coagulopathy.
  • Donation or loss of a significant volume (more than 100 mL) of blood or plasma or during the 3 months prior to the start of the study
  • Subjects who have participated in any type of clinical study during the 3 months prior to the start of the study
  • History of any gastrointestinal surgery that could affect drug absorption
  • Presence of fainting history or fear to blood collection
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Levonorgestrel and Ethinyl estradiol Test Product

    Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.

    Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug

  • Active comparator
    Levonorgestrel and Ethinyl estradiol Reference Product

    Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.

    Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product

Interventions

  • DrugLevonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug

    Drug page: Levonorgestrel

    Bioequivalence

    Also known as: Investigational Medicinal Product

  • DrugLevonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product

    Drug page: Levonorgestrel

    Bioequivalence

    Also known as: Microgynon CD (Trademark)

06

What researchers measure

Primary outcomes

  1. Total Ethinyl estradiol: area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72)

    19 samples up to 72 hours will be taken after the administration in each period.

    Time frame: From tablet intake and up to 72 hours after tablet intake

  2. Total Levonorgestrel: area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72)

    19 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  3. Total Ethinyl estradiol: area under the plasma concentration-time curve from 0 to time t (AUC0-t)

    19 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  4. Total Levonorgestrel: area under the plasma concentration-time curve from 0 to time t (AUC0-t)

    19 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  5. Total Ethinyl estradiol: Maximum plasma concentration (Cmax)

    19 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  6. Total Levonorgestrel: Maximum plasma concentration (Cmax)

    19 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  7. Total Levonorgestrel: Time to achieve maximum plasma concentration (tmax)

    19 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  8. Total Ethinyl estradiol: Time to achieve maximum plasma concentration (tmax)

    19 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

07

Study locations

1 site
  • Innolab
    Santiago, 7510491, Chile
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Oct 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2020
First posted
Jan 18, 2020
StartActual
Oct 24, 2020
Primary completionActual
Oct 31, 2020
CompletionActual
Nov 17, 2020
Last update
Feb 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04230070
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Oct 24, 2020
Primary completion
Oct 31, 2020
Completion
Nov 17, 2020
Last update
Feb 10, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levonorgestrel

Start the discussion